Paper Details

  1. Home
  2. Paper Details

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Author: AhmadiTahamtan, BahlisNizar J, BelchAndrew, BerdejaJesus, BladéJoan, CallanderNatalie, ChariAjai, FengHuaibao, GhariboMecide, JakubowiakAndrzej, KhanImran, KrishnanAmrita, LeBlancRichard, LisbySteen, LonialSagar, MateosMaria Victoria, MazumderAmitabha, OriolAlbert, OrlowskiRobert Z, RichardsonPaul G, ScottEmma C, SebagMichael, SinghalSeema, StevensDon A, SutherlandHeather J, UhlarClarissa M, UsmaniSaad Z, VescioRobert A, VoorheesPeter M, WeissBrendan M, WhiteDarrell, de la RubiaJavier

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favorable safety profile.
Paper Details　
Original Abstract of the Article :
BACKGROUND: New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38-targeted monoclonal antibody, in patients with refractory multiple myeloma. METHODS: In this open-label, mult...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(15)01120-4

データ提供：米国国立医学図書館（NLM）

A New Hope for Refractory Multiple Myeloma: Daratumumab Monotherapy

Multiple myeloma, a cancer of plasma cells, poses a significant challenge in oncology. This research explores the potential of daratumumab, a novel monoclonal antibody that targets CD38, as a treatment option for patients with multiple myeloma that has become resistant to conventional therapies. The study utilizes a randomized, phase 2 trial to evaluate the efficacy and safety of daratumumab monotherapy in a heavily pretreated patient population. The results of the trial provide valuable insights into the potential of daratumumab as a promising new treatment strategy for refractory multiple myeloma.

Promising Results for a Challenging Disease

The study found that daratumumab monotherapy demonstrated encouraging efficacy in patients with refractory multiple myeloma, achieving a response rate of 29.2%. The median duration of response was 7.4 months, and progression-free survival was 3.7 months. The favorable safety profile of daratumumab suggests that it can be well tolerated by patients who have already undergone extensive treatment. These findings offer a glimmer of hope for patients who have exhausted traditional treatment options.

Hope for the Future: Addressing Multiple Myeloma

This study underscores the importance of developing innovative therapies for refractory multiple myeloma. The emergence of daratumumab as a potential new treatment option offers a beacon of hope for patients struggling with this challenging disease. Further research is needed to fully understand the long-term efficacy and safety of daratumumab and its potential to improve the quality of life for patients with multiple myeloma.

Dr.Camel's Conclusion

The sands of time often shift in the desert of cancer research, but this study offers a ray of hope for those facing refractory multiple myeloma. Daratumumab, a novel monoclonal antibody, demonstrates promising efficacy in a heavily pretreated patient population. While more research is needed, this study is a testament to the power of innovation and the tireless pursuit of effective therapies for this challenging disease.

Date :
  1. Date Completed 2016-05-09
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

26778538

DOI: Digital Object Identifier

10.1016/S0140-6736(15)01120-4

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.